麝香保心丸联合曲美他嗪治疗老年缺血性心肌病心力衰竭疗效的Meta分析  

Clinical efficacy of Shexiang Baoxin Wan combining trimetazidine in treatment of ischemic cardiomyopathy and heart failure in elderly patients: A Meta-analysis

作　　者：林新铎[1] 王家宁[1] 唐俊明[1] 杨建业[1] 张蕾[1] 姜峰波 张旭阳[3] LIN Xin-duo;WANG Jia-ning;TANG Jun-ming;YANG Jian-ye;ZHANG Lei;JIANG Feng-bo;ZHANG Xu-yang(Institute of Clinical Medicine,Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China)

机构地区：[1]湖北医药学院附属人民医院临床医学研究所,十堰442000 [2]湖北医药学院附属人民医院神经内科,十堰442000 [3]湖北医药学院附属人民医院血液内科,十堰442000

出　　处：《中国循证心血管医学杂志》2016年第10期1162-1166,共5页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：国家自然科学基金(81270221)

摘　　要：目的探讨麝香保心丸联合曲美他嗪治疗老年缺血性心肌病心力衰竭的临床疗效。方法应用计算机在Cochrane Library、Pub Med、National Technical Information Service(NTIS)、PEDro、Embase、中国期刊全文数据库(CNKI)、万方数据库和维普数据库(VIP)等电子数据库中检索2016年3月31日以前有关麝香保心丸联合曲美他嗪治疗老年缺血性心肌病心力衰竭的临床随机对照试验。由2名评价员按照纳入和排除标准独立选择文献并提取资料,交叉核对并进行方法学质量评估,应用Rev Man5.2软件对所提取的数据进行Meta评价。结果对纳入的12个随机对照试验进行Meta分析,结果显示与对照组相比左室射血分数明显增加(SMD=1.55,95%CI:0.85~2.25)、左室舒张末期内径显著降低(SMD=-1.57,95%CI:-1.91^-1.22)、6 min步行距离明显增加(WMD=56.98,95%CI:42.76~71.19)、临床疗效显著改善(RR=1.30,95%CI:1.23~1.38),其差异均具有统计学意义(P均<0.05)。结论现有证据表明麝香保心丸联合曲美他嗪治疗老年缺血性心肌病心力衰竭后患者左室射血分数、左室舒张末期内径、6 min步行距离、临床疗效得到显著改善。Objective To investigate the clinical efficacy of Shexiang Baoxin Wan combining trimetazidine intreatment of ischemic cardiomyopathy and heart failure in elderly patients. Methods The databases of CochraneLibrary, PubMed, NTIS, PEDro, EMbase, CNKI, WanFang Database and VIP Database were retrieved withcomputer before Mar. 31, 2016 for collecting clinical randomized controlled trials (RCT) about Shexiang BaoxinWan combining trimetazidine in treatment of ischemic cardiomyopathy and heart failure in elderly patients. AllRCT were selected by 2 reviewers independently according to inclusion and exclusion criteria, and data wasextracted, checked crossly and given methodological quality evaluation. The extracted data was given a Metaanalysisby using RevMan 5.2 software. Results The results of the Meta-analysis on 12 clinical RCT showed thatleft ventricular ejection fraction (LVEF) increased significantly (SMD=1.55, 95%CI: 0.85~2.25), left ventricularend-diastolic inner diameter (LVEDd) decreased significantly (SMD=-1.57, 95%CI: -1.91~ -1.22), 6-minute walktest (6MWT) increased significantly (WMD=56.98, 95%CI: 42.76~71.19) and clinical efficacy was significantlyimproved (RR=1.30, 95%CI: 1.23~1.38) in treatment group compared with control group (all P<0.05). ConclusionThe current evidence indicates that LVEF, LVEDd, 6MWT and clinical efficacy are significantly improved in elderlypatients with ischemic cardiomyopathy and heart failure treated with Shexiang Baoxin Wan combining trimetazidine.

关 键 词：麝香保心丸 曲美他嗪 老年缺血性心肌病 心力衰竭 META分析 

分 类 号：R[医药卫生]